Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

home / authors / jeanny-aragon-ching,-md,-inova-schar-cancer-institute

Articles

Bright Future in Advanced Urothelial Cancer

Bright Future in Advanced Urothelial Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Sequencing Considerations in mUC after Frontline IO

Sequencing Considerations in mUC after Frontline IO

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Metastatic Bladder Cancer: Progression After Maintenance

Metastatic Bladder Cancer: Progression After Maintenance

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Educating Patients on Maintenance Therapy in mUC

Educating Patients on Maintenance Therapy in mUC

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Changing the Standard of Care in Metastatic Bladder Cancer

Changing the Standard of Care in Metastatic Bladder Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Practical Management of AEs in Metastatic Bladder Cancer

Practical Management of AEs in Metastatic Bladder Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Safety Data from JAVELIN Bladder 100

Safety Data from JAVELIN Bladder 100

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Increased Survival Outcomes with Switch Maintenance in mUC

Increased Survival Outcomes with Switch Maintenance in mUC

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Switch Maintenance Strategy for Metastatic Bladder Cancer

Switch Maintenance Strategy for Metastatic Bladder Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Value of PD-L1 Testing in Metastatic Urothelial Cancer

Value of PD-L1 Testing in Metastatic Urothelial Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

PD-L1 Expression in Metastatic Urothelial Cancer

PD-L1 Expression in Metastatic Urothelial Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Current Status of Therapy: Metastatic Urothelial Cancer

Current Status of Therapy: Metastatic Urothelial Cancer

Shilpa Gupta, MD, Cleveland Clinic;Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
August 26th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need